Multiple myeloma typically affects elderly patients. Approximately one-third of patients are
older than 75 years at diagnosis. Moreover, at least 30% are frail, both due to disease …

The median overall survival in multiple myeloma is rapidly approaching 10 years; however,
in nearly a fifth of patients the prognosis remains poor. Therefore, the modern‐day …

This first validation of the International Myeloma Working Group geriatric assessment in 125
newly diagnosed multiple myeloma patients was performed using the International Myeloma …

Recommendations are based on a review of the literature using Medline, PubMed, Embase,
Central, Web of Science searches from the beginning of 2013 up to July 2019. The following …

Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma
(MM) ineligible for stem-cell transplantation examined updated outcomes and impact of …

Multiple myeloma (MM) patient frailty has been delineated primarily by age and ECOG
performance score (PS) and recently by the IMWG frailty score based on functional status …

The phase 3 POLLUX and CASTOR studies demonstrated superior benefit of daratumumab
plus lenalidomide/dexamethasone or bortezomib/dexamethasone in relapsed/refractory …

Background This study aimed to investigate the distribution of multiple myeloma (MM) in
India and provide a comprehensive narrative about its incidence, including differential …

The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-
wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian …

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a multifunctional neuropeptide
with well-known anti-inflammatory, antioxidant, antitumor, and immunomodulatory effects …